Trial Profile
Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Sorafenib in Combination With Irinotecan
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 05 Sep 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Feb 2017 Planned End Date changed from 1 Feb 2020 to 29 Feb 2020.
- 14 Feb 2017 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.